Antibodies by Design, JPT Announce Cooperation Agreement

Antibodies by Design, a division of MorphoSys, and JPT Peptide Technologies, a wholly owned subsidiary of Jerini, announced the start of a co-marketing agreement between the two specialist companies. Within the scope of this agreement the parties agree to co-market the rapid generation of monoclonal antibodies by Antibodies by Design and the complementary peptide-based services and products from JPT. Each partner will offer the services of the other to its customers throughout the worldwide market, with exception of Japan.

Business Wire

(http://home.businesswire.com/portal/site/google/index.jsp?ndmViewId=news_view&newsId=20050418005525&newsLang=en)